FEMY
Femasys Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.90
P/S
5.52
EV/EBITDA
-0.86
DCF Value
$-3.31
FCF Yield
-187.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-767.0%
Net Margin
-812.3%
ROE
-534.9%
ROA
0.0%
ROIC
558.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $813.4K | $-4.0M | $0.02 |
| FY 2025 | $2.3M | $-18.6M | $-0.47 |
| Q3 2025 | $729.4K | $-4.2M | $-0.10 |
| Q2 2025 | $409.3K | $-4.6M | $-0.16 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-2.53
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.